Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR2 RYR3	1.40e-05	4	31	2	GO:0005219
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR2 RYR3	3.49e-05	6	31	2	GO:0048763
GeneOntologyMolecularFunction	promoter-specific chromatin binding	HSF1 TAF1L ZC3H4	2.86e-04	83	31	3	GO:1990841
GeneOntologyMolecularFunction	intracellularly gated calcium channel activity	RYR2 RYR3	3.51e-04	18	31	2	GO:0015278
GeneOntologyMolecularFunction	chromatin binding	RAD21L1 TPR HSF1 POLR3GL TAF1L ZC3H4	8.39e-04	739	31	6	GO:0003682
GeneOntologyMolecularFunction	calcium channel activity	CACNA1H RYR2 RYR3	1.04e-03	129	31	3	GO:0005262
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	RYR2 RYR3	1.05e-03	31	31	2	GO:0099604
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	RYR2 RYR3	1.20e-03	33	31	2	GO:0005217
GeneOntologyMolecularFunction	calcium ion transmembrane transporter activity	CACNA1H RYR2 RYR3	1.63e-03	151	31	3	GO:0015085
GeneOntologyMolecularFunction	cell adhesion molecule binding	TJP2 ITGA6 NFASC FGG TJP3	2.13e-03	599	31	5	GO:0050839
GeneOntologyMolecularFunction	extracellular matrix structural constituent	MFAP4 COL12A1 FGG	3.04e-03	188	31	3	GO:0005201
GeneOntologyBiologicalProcess	positive regulation of blood-brain barrier permeability	TJP2 TJP3	2.18e-05	5	31	2	GO:1905605
GeneOntologyBiologicalProcess	cellular response to alkaloid	RYR2 RYR3 RECQL5	2.92e-05	40	31	3	GO:0071312
GeneOntologyBiologicalProcess	response to alkaloid	RYR2 RYR3 RECQL5 PGR	3.56e-05	125	31	4	GO:0043279
GeneOntologyBiologicalProcess	replication-born double-strand break repair via sister chromatid exchange	RAD21L1 RECQL5	6.09e-05	8	31	2	GO:1990414
GeneOntologyBiologicalProcess	regulation of blood-brain barrier permeability	TJP2 TJP3	9.76e-05	10	31	2	GO:1905603
GeneOntologyBiologicalProcess	cellular response to caffeine	RYR2 RYR3	1.19e-04	11	31	2	GO:0071313
GeneOntologyBiologicalProcess	cellular response to purine-containing compound	RYR2 RYR3	1.97e-04	14	31	2	GO:0071415
GeneOntologyBiologicalProcess	cellular response to organic cyclic compound	ITGA6 HSF1 RYR2 RYR3 RECQL5 PGR	2.45e-04	605	31	6	GO:0071407
GeneOntologyBiologicalProcess	establishment of endothelial intestinal barrier	TJP2 TJP3	2.93e-04	17	31	2	GO:0090557
GeneOntologyBiologicalProcess	response to metal ion	FGG ATP7B HSF1 RYR2 RYR3	3.55e-04	415	31	5	GO:0010038
GeneOntologyBiologicalProcess	response to caffeine	RYR2 RYR3	4.51e-04	21	31	2	GO:0031000
GeneOntologyBiologicalProcess	positive regulation of vascular permeability	TJP2 TJP3	5.42e-04	23	31	2	GO:0043117
GeneOntologyBiologicalProcess	negative regulation of DNA-templated transcription, elongation	ZC3H4 RECQL5	5.42e-04	23	31	2	GO:0032785
GeneOntologyBiologicalProcess	maintenance of location in cell	ATP7B RYR2 RYR3 PGR	5.85e-04	259	31	4	GO:0051651
GeneOntologyBiologicalProcess	protein localization to cell-cell junction	TJP2 TJP3	5.91e-04	24	31	2	GO:0150105
GeneOntologyBiologicalProcess	negative regulation of cytosolic calcium ion concentration	RYR2 RYR3	6.42e-04	25	31	2	GO:0051481
GeneOntologyBiologicalProcess	response to magnesium ion	RYR2 RYR3	6.42e-04	25	31	2	GO:0032026
GeneOntologyBiologicalProcess	regulation of spindle checkpoint	TPR HSF1	6.95e-04	26	31	2	GO:0090231
GeneOntologyBiologicalProcess	cellular response to copper ion	ATP7B HSF1	7.50e-04	27	31	2	GO:0071280
GeneOntologyBiologicalProcess	response to organic cyclic compound	ITGA6 TPR HSF1 RYR2 RYR3 RECQL5 PGR	7.70e-04	1048	31	7	GO:0014070
GeneOntologyBiologicalProcess	cell-cell adhesion	CHL1 TJP2 ITGA6 NFASC FGG CELSR2 TJP3	9.05e-04	1077	31	7	GO:0098609
GeneOntologyCellularComponent	tight junction	TJP2 NFASC ATP7B TJP3	5.12e-05	139	31	4	GO:0070160
GeneOntologyCellularComponent	apical junction complex	TJP2 NFASC ATP7B TJP3	8.43e-05	158	31	4	GO:0043296
GeneOntologyCellularComponent	calcium channel complex	CACNA1H RYR2 RYR3	1.71e-04	73	31	3	GO:0034704
GeneOntologyCellularComponent	pronucleus	HSF1 TAF1L	7.85e-04	28	31	2	GO:0045120
GeneOntologyCellularComponent	bicellular tight junction	TJP2 ATP7B TJP3	9.51e-04	131	31	3	GO:0005923
GeneOntologyCellularComponent	cell-cell junction	TJP2 ITGA6 NFASC ATP7B TJP3	1.64e-03	591	31	5	GO:0005911
GeneOntologyCellularComponent	sarcoplasmic reticulum membrane	RYR2 RYR3	2.03e-03	45	31	2	GO:0033017
GeneOntologyCellularComponent	smooth endoplasmic reticulum	RYR2 RYR3	2.12e-03	46	31	2	GO:0005790
GeneOntologyCellularComponent	sarcolemma	CACNA1H RYR2 RYR3	2.75e-03	190	31	3	GO:0042383
Domain	RyR	RYR2 RYR3	7.48e-06	3	30	2	PF02026
Domain	Ryanodine_rcpt	RYR2 RYR3	7.48e-06	3	30	2	IPR003032
Domain	RR_TM4-6	RYR2 RYR3	7.48e-06	3	30	2	PF06459
Domain	ZO	TJP2 TJP3	7.48e-06	3	30	2	IPR005417
Domain	Ryanrecept_TM4-6	RYR2 RYR3	7.48e-06	3	30	2	IPR009460
Domain	Ryan_recept	RYR2 RYR3	7.48e-06	3	30	2	IPR013333
Domain	Neurofascin/L1/NrCAM_C	CHL1 NFASC	1.49e-05	4	30	2	IPR026966
Domain	Bravo_FIGEY	CHL1 NFASC	1.49e-05	4	30	2	PF13882
Domain	ConA-like_dom	COL12A1 CELSR2 HNRNPUL2 RYR2 RYR3	2.38e-05	219	30	5	IPR013320
Domain	RIH_assoc	RYR2 RYR3	3.73e-05	6	30	2	PF08454
Domain	RIH_assoc-dom	RYR2 RYR3	3.73e-05	6	30	2	IPR013662
Domain	RYDR_ITPR	RYR2 RYR3	3.73e-05	6	30	2	PF01365
Domain	RIH_dom	RYR2 RYR3	3.73e-05	6	30	2	IPR000699
Domain	Ins145_P3_rcpt	RYR2 RYR3	3.73e-05	6	30	2	IPR014821
Domain	Ryanodine_recept-rel	RYR2 RYR3	3.73e-05	6	30	2	IPR015925
Domain	Ins145_P3_rec	RYR2 RYR3	3.73e-05	6	30	2	PF08709
Domain	-	RYR2 RYR3	3.73e-05	6	30	2	1.25.10.30
Domain	MIR	RYR2 RYR3	1.11e-04	10	30	2	PS50919
Domain	MIR	RYR2 RYR3	1.11e-04	10	30	2	PF02815
Domain	MIR	RYR2 RYR3	1.11e-04	10	30	2	SM00472
Domain	MIR_motif	RYR2 RYR3	1.11e-04	10	30	2	IPR016093
Domain	SH3_2	TJP2 MIA2 TJP3	3.50e-04	86	30	3	IPR011511
Domain	SH3_2	TJP2 MIA2 TJP3	3.50e-04	86	30	3	PF07653
Domain	SPRY	HNRNPUL2 RYR2 RYR3	3.62e-04	87	30	3	SM00449
Domain	SPRY	HNRNPUL2 RYR2 RYR3	4.54e-04	94	30	3	PF00622
Domain	SPRY_dom	HNRNPUL2 RYR2 RYR3	4.54e-04	94	30	3	IPR003877
Domain	B30.2/SPRY	HNRNPUL2 RYR2 RYR3	4.69e-04	95	30	3	IPR001870
Domain	B302_SPRY	HNRNPUL2 RYR2 RYR3	4.69e-04	95	30	3	PS50188
Domain	GUANYLATE_KINASE_2	TJP2 TJP3	6.18e-04	23	30	2	PS50052
Domain	GUANYLATE_KINASE_1	TJP2 TJP3	6.18e-04	23	30	2	PS00856
Domain	-	MFAP4 FGG	6.73e-04	24	30	2	4.10.530.10
Domain	Fibrinogen_a/b/g_C_2	MFAP4 FGG	6.73e-04	24	30	2	IPR014715
Domain	Guanylate_kin	TJP2 TJP3	7.91e-04	26	30	2	PF00625
Domain	GK/Ca_channel_bsu	TJP2 TJP3	7.91e-04	26	30	2	IPR008145
Domain	Guanylate_kin-like_dom	TJP2 TJP3	7.91e-04	26	30	2	IPR008144
Domain	GuKc	TJP2 TJP3	7.91e-04	26	30	2	SM00072
Domain	Ion_trans_dom	CACNA1H RYR2 RYR3	7.97e-04	114	30	3	IPR005821
Domain	Ion_trans	CACNA1H RYR2 RYR3	7.97e-04	114	30	3	PF00520
Domain	Fibrinogen_C	MFAP4 FGG	8.54e-04	27	30	2	PF00147
Domain	FBG	MFAP4 FGG	9.86e-04	29	30	2	SM00186
Domain	-	MFAP4 FGG	1.06e-03	30	30	2	3.90.215.10
Domain	Fibrinogen_a/b/g_C_1	MFAP4 FGG	1.06e-03	30	30	2	IPR014716
Domain	Fibrinogen_a/b/g_C_dom	MFAP4 FGG	1.20e-03	32	30	2	IPR002181
Domain	FIBRINOGEN_C_2	MFAP4 FGG	1.20e-03	32	30	2	PS51406
Domain	FIBRINOGEN_C_1	MFAP4 FGG	1.20e-03	32	30	2	PS00514
Domain	fn3	CHL1 NFASC COL12A1	2.19e-03	162	30	3	PF00041
Domain	FN3	CHL1 NFASC COL12A1	3.19e-03	185	30	3	SM00060
Domain	Laminin_G	COL12A1 CELSR2	3.90e-03	58	30	2	IPR001791
Domain	FN3	CHL1 NFASC COL12A1	3.91e-03	199	30	3	PS50853
Domain	FN3_dom	CHL1 NFASC COL12A1	4.49e-03	209	30	3	IPR003961
Pubmed	HSF1-TPR interaction facilitates export of stress-induced HSP70 mRNA.	TPR HSF1	7.69e-07	2	31	2	17897941
Pubmed	The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors.	RYR2 RYR3	7.69e-07	2	31	2	14550562
Pubmed	Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease.	RYR2 RYR3	7.69e-07	2	31	2	21531043
Pubmed	Modulation of calcium signalling by dominant negative splice variant of ryanodine receptor subtype 3 in native smooth muscle cells.	RYR2 RYR3	7.69e-07	2	31	2	16678258
Pubmed	Decreased expression of ryanodine receptors alters calcium-induced calcium release mechanism in mdx duodenal myocytes.	RYR2 RYR3	7.69e-07	2	31	2	14985349
Pubmed	Tissue-specific alternative splicing of mouse brain type ryanodine receptor/calcium release channel mRNA.	RYR2 RYR3	7.69e-07	2	31	2	8898078
Pubmed	Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells.	RYR2 RYR3	2.31e-06	3	31	2	9242641
Pubmed	Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.	RYR2 RYR3	2.31e-06	3	31	2	18403125
Pubmed	Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes.	RYR2 RYR3	2.31e-06	3	31	2	22948152
Pubmed	Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain.	RYR2 RYR3	2.31e-06	3	31	2	10788707
Pubmed	RYR2 proteins contribute to the formation of Ca(2+) sparks in smooth muscle.	RYR2 RYR3	2.31e-06	3	31	2	15024040
Pubmed	Heterogeneous gene expression and functional activity of ryanodine receptors in resistance and conduit pulmonary as well as mesenteric artery smooth muscle cells.	RYR2 RYR3	2.31e-06	3	31	2	18434746
Pubmed	Control of Neuronal Ryanodine Receptor-Mediated Calcium Signaling by Calsenilin.	RYR2 RYR3	2.31e-06	3	31	2	29730765
Pubmed	Roles of ZO-1 and ZO-2 in establishment of the belt-like adherens and tight junctions with paracellular permselective barrier function.	TJP2 TJP3	2.31e-06	3	31	2	19538286
Pubmed	Calcineurin upregulates local Ca(2+) signaling through ryanodine receptor-1 in airway smooth muscle cells.	RYR2 RYR3	2.31e-06	3	31	2	25239916
Pubmed	Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor.	RYR2 RYR3	2.31e-06	3	31	2	7621815
Pubmed	Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion.	TJP2 TJP3	2.31e-06	3	31	2	25486565
Pubmed	SPRY domains in ryanodine receptors (Ca(2+)-release channels).	RYR2 RYR3	2.31e-06	3	31	2	9204703
Pubmed	A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice.	RYR2 RYR3	2.31e-06	3	31	2	18643873
Pubmed	Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2).	RYR2 RYR3	2.31e-06	3	31	2	11159936
Pubmed	The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues.	RYR2 RYR3	2.31e-06	3	31	2	7876312
Pubmed	Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.	RYR2 RYR3	2.31e-06	3	31	2	21881589
Pubmed	Nucleoporin TPR (translocated promoter region, nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma.	TPR HSF1	2.31e-06	3	31	2	32207633
Pubmed	Molecular identification of the ryanodine receptor pore-forming segment.	RYR2 RYR3	2.31e-06	3	31	2	10473538
Pubmed	Chromosomal localization of murine ryanodine receptor genes RYR1, RYR2, and RYR3 by in situ hybridization.	RYR2 RYR3	2.31e-06	3	31	2	7959768
Pubmed	Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors).	RYR2 RYR3	2.31e-06	3	31	2	12213830
Pubmed	The organization of proteins in the human red blood cell membrane. A review.	RYR2 RYR3	2.31e-06	3	31	2	4600883
Pubmed	Regulation of mouse egg activation: presence of ryanodine receptors and effects of microinjected ryanodine and cyclic ADP ribose on uninseminated and inseminated eggs.	RYR2 RYR3	2.31e-06	3	31	2	7635066
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	TJP2 TPR PPIG AFTPH HSF1 ZC3H4 MOCOS	4.34e-06	774	31	7	15302935
Pubmed	Characterization of the ubinuclein protein as a new member of the nuclear and adhesion complex components (NACos).	TJP2 TJP3	4.61e-06	4	31	2	18823282
Pubmed	Requirement for the ryanodine receptor type 3 for efficient contraction in neonatal skeletal muscles.	RYR2 RYR3	4.61e-06	4	31	2	9384575
Pubmed	Structural and functional evolution of the L1 family: are four adhesion molecules better than one?	CHL1 NFASC	4.61e-06	4	31	2	10662501
Pubmed	A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.	RYR2 RYR3	4.61e-06	4	31	2	18206662
Pubmed	Novel prognostic biomarkers of gastric cancer based on gene expression microarray: COL12A1, GSTA3, FGA and FGG.	COL12A1 FGG	4.61e-06	4	31	2	30106150
Pubmed	Partial cloning and differential expression of ryanodine receptor/calcium-release channel genes in human tissues including the hippocampus and cerebellum.	RYR2 RYR3	4.61e-06	4	31	2	9607712
Pubmed	Dynamic assembly of tight junction-associated proteins ZO-1, ZO-2, ZO-3 and occludin during mouse tooth development.	TJP2 TJP3	4.61e-06	4	31	2	12507281
Pubmed	Conserved and divergent functions of Nfix in skeletal muscle development during vertebrate evolution.	RYR2 RYR3	4.61e-06	4	31	2	23482488
Pubmed	Ryanodine receptor calcium release channels: lessons from structure-function studies.	RYR2 RYR3	4.61e-06	4	31	2	23413940
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	TJP2 TPR AFTPH HNRNPUL2 ZC3H4 MOCOS	4.81e-06	503	31	6	16964243
Pubmed	Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development.	TJP2 TJP3	7.68e-06	5	31	2	18172007
Pubmed	Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3.	TJP2 TJP3	7.68e-06	5	31	2	10575001
Pubmed	Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases.	RYR2 RYR3	7.68e-06	5	31	2	33060591
Pubmed	Protein kinase C-epsilon regulates local calcium signaling in airway smooth muscle cells.	RYR2 RYR3	7.68e-06	5	31	2	19011160
Pubmed	Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons.	RYR2 RYR3	7.68e-06	5	31	2	23918386
Pubmed	Membrane depolarization causes a direct activation of G protein-coupled receptors leading to local Ca2+ release in smooth muscle.	RYR2 RYR3	1.15e-05	6	31	2	19549818
Pubmed	HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization.	RYR2 RYR3	1.15e-05	6	31	2	19009018
Pubmed	Rectification of muscle and nerve deficits in paralyzed ryanodine receptor type 1 mutant embryos.	RYR2 RYR3	1.15e-05	6	31	2	26025922
Pubmed	Roles of I(f) and intracellular Ca2+ release in spontaneous activity of ventricular cardiomyocytes during murine embryonic development.	RYR2 RYR3	1.15e-05	6	31	2	23463619
Pubmed	IP3Rs are sufficient for dendritic cell Ca2+ signaling in the absence of RyR1.	RYR2 RYR3	1.15e-05	6	31	2	16844763
Pubmed	FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells.	RYR2 RYR3	1.15e-05	6	31	2	14592808
Pubmed	A calcium-induced calcium release mechanism supports luteinizing hormone-induced testosterone secretion in mouse Leydig cells.	RYR2 RYR3	1.15e-05	6	31	2	20519450
Pubmed	Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging.	RYR2 RYR3	1.15e-05	6	31	2	25966694
Pubmed	EphB regulates L1 phosphorylation during retinocollicular mapping.	CHL1 NFASC	1.61e-05	7	31	2	22579729
Pubmed	Developmental expression of the calcium release channels during early neurogenesis of the mouse cerebral cortex.	RYR2 RYR3	1.61e-05	7	31	2	11860456
Pubmed	Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax.	RYR2 RYR3	1.61e-05	7	31	2	20962236
Pubmed	Sequential docking, molecular differentiation, and positioning of T-Tubule/SR junctions in developing mouse skeletal muscle.	RYR2 RYR3	2.15e-05	8	31	2	11784029
Pubmed	Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and beta-cell death.	RYR2 RYR3	2.15e-05	8	31	2	19033399
Pubmed	New molecular components supporting ryanodine receptor-mediated Ca(2+) release: roles of junctophilin and TRIC channel in embryonic cardiomyocytes.	RYR2 RYR3	5.05e-05	12	31	2	19095005
Pubmed	Alpha6beta4 integrin and dystroglycan cooperate to stabilize the myelin sheath.	ITGA6 NFASC	5.05e-05	12	31	2	18579745
Pubmed	A role for Nr-CAM in the patterning of binocular visual pathways.	CHL1 NFASC	5.05e-05	12	31	2	16701205
Pubmed	Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins.	TJP2 TJP3	5.05e-05	12	31	2	10601346
Pubmed	Calcium handling precedes cardiac differentiation to initiate the first heartbeat.	CACNA1H RYR2	1.04e-04	17	31	2	27725084
Pubmed	Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells.	TJP2 TJP3	1.60e-04	21	31	2	18353970
Pubmed	Non-EST-based prediction of novel alternatively spliced cassette exons with cell signaling function in Caenorhabditis elegans and human.	ITGA6 RECQL5	2.10e-04	24	31	2	17452356
Pubmed	Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.	MFAP4 COL12A1 FGG	2.37e-04	135	31	3	28675934
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	TJP2 C5orf34 AFTPH POLD2 MOCOS TJP3	2.71e-04	1038	31	6	26673895
Pubmed	Gene expression in the developing mouse retina by EST sequencing and microarray analysis.	HSF1 HNRNPUL2 RYR2	2.75e-04	142	31	3	11812828
Pubmed	Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.	MFAP4 COL12A1 FGG	3.43e-04	153	31	3	25037231
Pubmed	Regulation of endodermal differentiation of human embryonic stem cells through integrin-ECM interactions.	ITGA6 COL12A1	3.75e-04	32	31	2	23154389
Pubmed	Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme.	TPR FGG HNRNPUL2 TAF1L	3.86e-04	390	31	4	17643375
Pubmed	An investigation into the human serum "interactome".	MIA2 RYR2 MOCOS	4.05e-04	162	31	3	15174051
Pubmed	LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.	CACNA1H RYR2	4.24e-04	34	31	2	26378152
Pubmed	The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.	MFAP4 COL12A1 FGG	4.43e-04	167	31	3	22159717
Pubmed	LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.	ITGA6 RYR2 RYR3	4.51e-04	168	31	3	30631154
Pubmed	Human variation in alcohol response is influenced by variation in neuronal signaling genes.	CACNA1H ATP7B RYR3	4.74e-04	171	31	3	20201926
Pubmed	Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development.	RYR2 RYR3	5.30e-04	38	31	2	30786075
Pubmed	Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach.	ITGA6 FGG	5.30e-04	38	31	2	16263699
Pubmed	YAP is essential for mechanical force production and epithelial cell proliferation during lung branching morphogenesis.	TJP2 ARHGEF17	5.87e-04	40	31	2	28323616
Pubmed	A comprehensive resource of interacting protein regions for refining human transcription factor networks.	PPIG RYR2 RYR3	6.54e-04	191	31	3	20195357
Pubmed	Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.	RYR2 RYR3 TJP3	6.95e-04	195	31	3	17110338
Cytoband	2q31.1	ITGA6 PPIG	1.49e-03	84	31	2	2q31.1
Cytoband	20p13	RAD21L1 DNAAF9	2.18e-03	102	31	2	20p13
Cytoband	Ensembl 112 genes in cytogenetic band chr20p13	RAD21L1 DNAAF9	3.15e-03	123	31	2	chr20p13
Cytoband	Ensembl 112 genes in cytogenetic band chr2q31	ITGA6 PPIG	6.46e-03	178	31	2	chr2q31
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR2 RYR3	4.24e-06	3	22	2	287
GeneFamily	Fibrinogen C domain containing	MFAP4 FGG	4.17e-04	25	22	2	554
GeneFamily	Calcium voltage-gated channel subunits\|Membrane associated guanylate kinases	TJP2 TJP3	4.51e-04	26	22	2	904
GeneFamily	Fibronectin type III domain containing	CHL1 NFASC COL12A1	9.26e-04	160	22	3	555
GeneFamily	PDZ domain containing	TJP2 TJP3	1.45e-02	152	22	2	1220
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	CHL1 NFASC	1.62e-02	161	22	2	593
GeneFamily	EF-hand domain containing	RYR2 RYR3	2.88e-02	219	22	2	863
Coexpression	BRUINS_UVC_RESPONSE_LATE	TJP2 TPR MFAP4 DNAAF9 COL12A1 HSF1 POLR3GL MOCOS	3.93e-05	1136	31	8	M2247
Coexpression	BRUINS_UVC_RESPONSE_LATE	TJP2 TPR MFAP4 DNAAF9 COL12A1 HSF1 POLR3GL MOCOS	5.73e-05	1198	31	8	MM1062
Coexpression	GSE17721_LPS_VS_POLYIC_8H_BMDC_DN	TJP2 MIA2 HNRNPUL2 MOCOS	8.64e-05	199	31	4	M3813
Coexpression	GSE17721_POLYIC_VS_CPG_6H_BMDC_UP	AFTPH MIA2 PARP8 MOCOS	8.81e-05	200	31	4	M3943
Coexpression	GSE28237_FOLLICULAR_VS_LATE_GC_BCELL_DN	TJP2 DNAAF9 HNRNPUL2 ZC3H4	8.81e-05	200	31	4	M4889
Coexpression	GSE15750_WT_VS_TRAF6KO_DAY10_EFF_CD8_TCELL_UP	TPR POLD2 PARP8 RECQL5	8.81e-05	200	31	4	M3573
Coexpression	DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP	COL12A1 CELSR2 PGR MOCOS	1.46e-04	228	31	4	M2151
Coexpression	SMID_BREAST_CANCER_BASAL_DN	MFAP4 CACNA1H FGG ATP7B PGR TJP3	1.47e-04	699	31	6	M4960
Coexpression	JONES_OVARY_T_CELL	ITGA6 MFAP4 COL12A1	1.70e-04	91	31	3	M48354
ToppCell	Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NFASC CACNA1H COL12A1 ARHGEF17 RYR2	1.98e-07	190	31	5	d6b3a92119b210974a32af3fe9875d60eb02761e
ToppCell	Mesenchymal-vascular_smooth_muscle_cell\|World / Lineage, Cell type, age group and donor	NFASC CACNA1H COL12A1 ARHGEF17 RYR2	2.03e-07	191	31	5	fd89fbc62aa1c73e0f659991e3bd726a0c97bd68
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	NFASC CACNA1H COL12A1 ARHGEF17 RYR2	2.09e-07	192	31	5	5000440dc1ed17e7474d340921bdff945646f27e
ToppCell	distal-mesenchymal-Vascular_Smooth_Muscle-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFASC MFAP4 CACNA1H COL12A1 RYR2	2.37e-07	197	31	5	da653dc7d216e202f390e5ab0245f243e3ed213b
ToppCell	Bronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H COL12A1 ARHGEF17	2.43e-07	198	31	5	705118a5db366b43ffd3389c60e4cb392ad3f2e6
ToppCell	distal-2-mesenchymal-Vascular_Smooth_Muscle\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFASC MFAP4 CACNA1H COL12A1 RYR2	2.43e-07	198	31	5	ce05ede69c167b2294630709bb0c223483a6ef75
ToppCell	Parenchymal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H COL12A1 ARHGEF17	2.49e-07	199	31	5	7c272a1aa7f3e931ad5d20809719d85b3bce4cb0
ToppCell	Tracheal-10x5prime-Stromal-Myofibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H ARHGEF17 RYR2	2.49e-07	199	31	5	0a145172787f40d0fdaf21188d539ffaf7ece3e4
ToppCell	distal-2-mesenchymal-Airway_Smooth_Muscle\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFASC MFAP4 CACNA1H COL12A1 PGR	2.49e-07	199	31	5	af226a6c50747dad9ca696463e715913b3ac17c0
ToppCell	Tracheal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_systemic_arterial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H ARHGEF17 RYR2	2.49e-07	199	31	5	c2903b1a4b91e94bbdaa909bacefe901255cf248
ToppCell	Parenchymal-10x5prime-Stromal-Myofibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H COL12A1 ARHGEF17	2.49e-07	199	31	5	20f760d92c351a1dac4cc0a424c443ea03a179fe
ToppCell	Bronchial-10x5prime-Stromal-Myofibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H ARHGEF17 RYR2	2.49e-07	199	31	5	ad75e5e26c37a97331164d7f77235ebd9a933a44
ToppCell	facs-Lung-3m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHL1 NFASC CACNA1H RYR2	3.30e-06	148	31	4	5983c4546f527a0b599cfcbd8a6cb937a1d6f895
ToppCell	TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Conventional_Leiomyosarcoma\|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9	NFASC CELSR2 RYR2 RYR3	3.77e-06	153	31	4	ec6fe6b8c884fa76adc7a0f9db041f7b1567a2ee
ToppCell	facs-Lung-nan-3m-Endothelial-Capillary_Type_1_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 NFASC CACNA1H RYR2	4.50e-06	160	31	4	f2cdee5a9e3b0eb125d6be7b5d239eb04333ae41
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NFASC ARHGEF17 RYR2 PGR	5.72e-06	170	31	4	5570c0e825bca77613bf0ebde620cf744fa1cb84
ToppCell	10x_5'_v1-Neoplastic-Stem-like-OPC-like\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 TJP2 NFASC ATP7B	6.41e-06	175	31	4	cc596907ea1a64ab7b5a8c7d4ad12e6ee59bfed9
ToppCell	10x_5'_v1-Neoplastic-Stem-like\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 TJP2 NFASC ATP7B	6.41e-06	175	31	4	a8400e7e47379901dcab5f2e364c3ff17765b4b9
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC COL12A1 ARHGEF17 PGR	6.41e-06	175	31	4	1b4cefae400bf756d09ece32d3f5c0bd4c6ad73f
ToppCell	10x_5'_v1-Neoplastic-Stem-like-OPC-like-OPC-like\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 TJP2 NFASC ATP7B	6.41e-06	175	31	4	8a3abf40146ae3459d97cdf865c1c8f6b92ac639
ToppCell	10x_5'_v1-Neoplastic-Stem-like-OPC-like-OPC-like-Z\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 TJP2 NFASC ATP7B	6.41e-06	175	31	4	378d2b79edac91fc74eee0fb42bb29dd9b07c36f
ToppCell	-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	RAD21L1 NFASC MFAP4 PGR	7.01e-06	179	31	4	10fadbaa1b6d21cbf9f354d717cc4c225619f4fd
ToppCell	Control-Stromal-SMC\|Control / Disease state, Lineage and Cell class	NFASC MFAP4 CACNA1H ARHGEF17	7.01e-06	179	31	4	1378051bc62009eec2dbecf3d5d89baedbeb84eb
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC COL12A1 ARHGEF17 PGR	7.32e-06	181	31	4	a2058d658f07ab6f0a28d2622f3090b4cde6f763
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC COL12A1 ARHGEF17 PGR	7.32e-06	181	31	4	526e858a848470b6d2d5248788004d9735ed3add
ToppCell	normal_Lung-Fibroblasts-Pericytes\|normal_Lung / Location, Cell class and cell subclass	CACNA1H COL12A1 ARHGEF17 RYR2	7.32e-06	181	31	4	f74941e49950027360d71ea3b205fc20c6929766
ToppCell	Pericytes-Donor_03\|World / lung cells shred on cell class, cell subclass, sample id	MFAP4 CACNA1H RYR2 PGR	7.65e-06	183	31	4	d04deef7cd4e1738227a6593b84874ce0168c773
ToppCell	tumor_Lung-Fibroblasts-Pericytes\|tumor_Lung / Location, Cell class and cell subclass	NFASC CACNA1H COL12A1 ARHGEF17	7.65e-06	183	31	4	a03dd563af9b15cb1f5de5732a229405a9f82d84
ToppCell	LPS_only-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1H ARHGEF17 RYR2 PGR	7.81e-06	184	31	4	327ff3ac8d2fecdd5d242bdc34f0dfdb1c59a68b
ToppCell	COVID-19-Fibroblasts-Pericytes\|COVID-19 / group, cell type (main and fine annotations)	NFASC CACNA1H ARHGEF17 RYR2	7.98e-06	185	31	4	4905adaeeffd353e089578e5ea614437dbe794e6
ToppCell	COVID-19-Fibroblasts-Airway_smooth_muscle\|COVID-19 / group, cell type (main and fine annotations)	NFASC CACNA1H COL12A1 RYR2	8.33e-06	187	31	4	464a0c3b92b778911b5f9cd73642e09e3472063a
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NFASC CACNA1H ARHGEF17 RYR2	8.33e-06	187	31	4	a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCell	IPF-Stromal-SMC\|World / Disease state, Lineage and Cell class	NFASC MFAP4 CACNA1H RYR2	8.51e-06	188	31	4	b66264e8f8d536ed2beec31e6746c687718f239b
ToppCell	IPF-Stromal-SMC\|IPF / Disease state, Lineage and Cell class	NFASC MFAP4 CACNA1H RYR2	8.51e-06	188	31	4	e98b24c0de41285f01f7ac194ff0a1b59fd5c333
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC CACNA1H ARHGEF17 RYR2	8.69e-06	189	31	4	2cfb4d12f75678d1619f4743838a0e954bd57761
ToppCell	5'-Adult-Appendix-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC MFAP4 CACNA1H RYR2	8.69e-06	189	31	4	b6bb4327b4560d07d2b728abcc5f144f428948a5
ToppCell	5'-Adult-Appendix-Mesenchymal-Pericytes\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC MFAP4 CACNA1H RYR2	8.69e-06	189	31	4	0daa8efac08dca9525d2b8d421952068cab4eb50
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC CACNA1H ARHGEF17 RYR2	8.69e-06	189	31	4	127ad2ba3e794df8cce2eee3e4171bccb5aad51b
ToppCell	COVID-19-Heart-EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	ITGA6 NFASC CACNA1H ARHGEF17	8.87e-06	190	31	4	a21653bfb7bafbc273f94fa7c13bfb48cf8fd562
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC CACNA1H COL12A1 RYR2	9.05e-06	191	31	4	04c4d454b57e29a8d1dcdeb4678ce71bdc29b77b
ToppCell	nucseq-Mesenchymal-Myocytic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1H COL12A1 ARHGEF17 RYR2	9.63e-06	194	31	4	2d66091097e106c7bee22e5281f50724700bdf8d
ToppCell	COVID-19-lung-Pericytes/_Smooth_Muscle\|lung / Disease (COVID-19 only), tissue and cell type	NFASC CACNA1H ARHGEF17 RYR2	9.63e-06	194	31	4	5e1e0513a54ec4cf0b247ec85c9fbc68dfac1da3
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	9.82e-06	195	31	4	e10b21e4dba4483efc4c82d6e395524246ca14a8
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	9.82e-06	195	31	4	9ab3c5b0fb12d406408122a535b717bfe184bbcf
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	9.82e-06	195	31	4	21263d138c81f6a0219f2cd93126cfafd35732b2
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_immune_recruiting\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	MFAP4 COL12A1 RYR2 PGR	1.00e-05	196	31	4	614a07334707eafe238d5cb7b080a3ca796a1920
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFASC MFAP4 CACNA1H COL12A1	1.00e-05	196	31	4	208ddedd29e1b9ca89cbb9b527c2e193a44cada2
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC CACNA1H ARHGEF17 RYR2	1.00e-05	196	31	4	ce6f7ddb8104471dc90347f427486379914d63b4
ToppCell	IPF-Stromal-Pericyte\|IPF / Disease state, Lineage and Cell class	NFASC CACNA1H ARHGEF17 RYR2	1.00e-05	196	31	4	8b6ff47ce5291d223f5e639fc45cd9267f418256
ToppCell	COVID-19-lung-Pericytes/_Smooth_Muscle\|COVID-19 / Disease (COVID-19 only), tissue and cell type	NFASC CACNA1H ARHGEF17 RYR2	1.00e-05	196	31	4	754a3613340932563cd8424d775e18b93c3a1aaa
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-Pericytes\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC CACNA1H ARHGEF17 RYR2	1.00e-05	196	31	4	6d7179decea512dd49bb2d5f6a4f5989349d52a9
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	1.02e-05	197	31	4	02e70768a917c5f097bc653e9e965a1000289d2e
ToppCell	Bronchial-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC CACNA1H RYR2 PGR	1.02e-05	197	31	4	bf0520a94ebb1d2f94de9f526d17e0b0e8fe7052
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC CACNA1H ARHGEF17 RYR2	1.02e-05	197	31	4	d16bb765afdc02406ffd7ce6a75bae72b66db66c
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	1.02e-05	197	31	4	d14e1f2ba94240c61eac435db43508a224d606a8
ToppCell	Bronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_systemic_arterial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC CACNA1H RYR2 PGR	1.02e-05	197	31	4	d1cb30ec4f3024541e9876c70bf63fe4d5c55bf1
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	1.02e-05	197	31	4	8b3bf5b45e49bf1c60e4d2703b470bb890385f67
ToppCell	Parenchymal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_systemic_arterial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC MFAP4 CACNA1H RYR2	1.02e-05	197	31	4	3f078be0b0f5e16edfb6d517beb20ac6178767f0
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-Pericytes\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFASC CACNA1H ARHGEF17 RYR2	1.02e-05	197	31	4	68c23c23b6924892f4c238cf2f5abc7927e04fbc
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_systemic_arterial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC CACNA1H ARHGEF17 RYR2	1.04e-05	198	31	4	7dd874b09c81cc512ccc1e9b65f290a5f94d736e
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	1.04e-05	198	31	4	daf367b699726286f0f0f7b4f3a6cf70c462fbeb
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	MFAP4 RYR2 RYR3 RECQL5	1.04e-05	198	31	4	0c4d2c68a42f8a9e964e2dd28092fe75f5216834
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC MFAP4 COL12A1 ARHGEF17	1.04e-05	198	31	4	54c8aa47040bc4977eed382514fc4ceae03f54f8
ToppCell	Bronchus_Control_(B.)-Stromal-TX-Smooth_muscle-2\|Bronchus_Control_(B.) / Sample group, Lineage and Cell type	CACNA1H ARHGEF17 RYR2 PGR	1.06e-05	199	31	4	2c5ad62919c64ea0242e0984bb9932d2d975f4e3
ToppCell	medial-mesenchymal-Vascular_Smooth_Muscle\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MFAP4 COL12A1 ARHGEF17 PGR	1.06e-05	199	31	4	74fe1737a0d63ef0bc49312f1b5823b5c39590dd
ToppCell	Parenchyma_COVID-19-Stromal-TX-Smooth_muscle-2\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	NFASC MFAP4 CACNA1H ARHGEF17	1.06e-05	199	31	4	c8bc05dece8b8a87d4a7a3e8112b924e15217de1
ToppCell	medial-mesenchymal-Vascular_Smooth_Muscle-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MFAP4 COL12A1 ARHGEF17 PGR	1.06e-05	199	31	4	263603264ff40ea8ef569cb43f8b84b5938438ab
ToppCell	medial-2-mesenchymal-Vascular_Smooth_Muscle\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MFAP4 COL12A1 ARHGEF17 PGR	1.06e-05	199	31	4	8ce0bcc53b3a955285d614459e45210104a6ed02
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Smooth_muscle-2-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NFASC MFAP4 CACNA1H ARHGEF17	1.06e-05	199	31	4	78b245d40c1e169ff2d26907b63d732e34529c5f
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Smooth_muscle-2\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NFASC MFAP4 CACNA1H ARHGEF17	1.06e-05	199	31	4	8e1e95c3a4b856415af208be6ad977e575bac189
ToppCell	cellseq2-Mesenchymal-Myocytic-Myocytic_2-VSMC\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NFASC MFAP4 CACNA1H ARHGEF17	1.09e-05	200	31	4	fc802dd73f048881d9ddafd1b79ab3ca654510e2
ToppCell	cellseq2-Mesenchymal-Myocytic-Myocytic_2\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NFASC MFAP4 CACNA1H ARHGEF17	1.09e-05	200	31	4	cffddb39960cd611428397c1ec4023192e8af5a7
ToppCell	distal-mesenchymal-Airway_Smooth_Muscle-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFASC MFAP4 CACNA1H COL12A1	1.09e-05	200	31	4	f09eaa52e11262ec47f3dcb4d890e240eaaa2b3d
ToppCell	Biopsy_Other_PF-Mesenchymal-Smooth_Muscle_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	NFASC MFAP4 CACNA1H ARHGEF17	1.09e-05	200	31	4	55ac281901309e30978da1f7489386e54489721e
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_submucosal-gland\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CHL1 CELSR2 RECQL5 MOCOS	1.09e-05	200	31	4	68b0f987c4fb8078675475f4f1e71302f832ef69
ToppCell	cellseq2-Mesenchymal-Myocytic\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NFASC MFAP4 CACNA1H ARHGEF17	1.09e-05	200	31	4	e60aebd20be8012fa2febf6585ed34ebd64ec9b3
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_submucosal-gland-SMG_Duct\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CHL1 CELSR2 RECQL5 MOCOS	1.09e-05	200	31	4	1b527bebbca1ef8c52449e40beb9358e37494e04
ToppCell	droplet-Liver-Hepatocytes-24m-Epithelial-Hepatocyte_(Midlobular)\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NFASC FGG MIA2	5.00e-05	103	31	3	3a0f02ce52c4e2eda5b987c89317280c08f90cb3
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-hematologic-erythrocytic\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	FGG RYR2 PGR	9.10e-05	126	31	3	cd02f3d4a3fadd24f3a298639b392f0354d227d2
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-hematologic\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	FGG RYR2 PGR	9.10e-05	126	31	3	f2ec5aa6c649ae1ff99519f6897cf207dc292edf
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-hematologic-erythrocytic-erythrocyte\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	FGG RYR2 PGR	9.10e-05	126	31	3	61a7e400cbc81691b21cd3c37376c1d19fec2270
ToppCell	LPS-antiTNF-Unknown-Endothelial-Pericyte_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NFASC RYR2 RYR3	1.04e-04	132	31	3	02491930097b75aaeedab9e8200711b0dc610944
ToppCell	LPS-antiTNF-Hematopoietic_Meg-Ery-Mes-Epi-like\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MFAP4 RYR2 TJP3	1.14e-04	136	31	3	a2063abe2d7c3277bfbe1514c8c66363cf04b248
ToppCell	LPS-antiTNF-Hematopoietic_Meg-Ery-Mes-Epi-like-Erythroid\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MFAP4 RYR2 TJP3	1.17e-04	137	31	3	8e2fa2ef8becace96a68bb85c002329110902fbb
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF17 RYR2 PGR	1.71e-04	156	31	3	6365b69ede98bc866e996bc52736b00401aacf6f
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC COL12A1 PGR	1.71e-04	156	31	3	363f1b661048d25895e2b8681c82894c957b29c0
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NFASC COL12A1 PGR	1.71e-04	156	31	3	d5207dbfbcfb885557ea1378dfe6a56d7102e94a
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic-Pericyte_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF17 RYR2 PGR	1.74e-04	157	31	3	bfec34182f052cf1c0d847ba53ea335d4d1190de
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell-D231\|Adult / Lineage, Cell type, age group and donor	COL12A1 ARHGEF17 RYR2	1.78e-04	158	31	3	8d64c0c9de910a3f4658778642d183c8b9b6f6a2
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	MFAP4 CACNA1H COL12A1	1.78e-04	158	31	3	84c0a215dabf697ada036c2b9592d0c61b5077de
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL12A1 RYR2 RYR3	1.84e-04	160	31	3	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Outer_Medullary_Collecting_Duct_Intercalated_Cell_Type_A\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CHL1 ITGA6 TJP3	1.84e-04	160	31	3	174a4ab27114efcc63be36929b80680be3c35c9b
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL12A1 RYR2 RYR3	1.84e-04	160	31	3	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	Adult-Mesenchymal-airway_smooth_muscle_cell-D122\|Adult / Lineage, Cell type, age group and donor	NFASC RYR2 RYR3	1.88e-04	161	31	3	64891f6f2ee1693c8481e951b9346e2f92d602e3
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligoastrocytoma\|TCGA-Brain / Sample_Type by Project: Shred V9	TJP2 DNAAF9 ARHGEF17	1.88e-04	161	31	3	347edb0de10850b7d16c40945751033289289c9b
ToppCell	Bronchial-10x5prime-Stromal-Schwann\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NFASC CELSR2 ARHGEF17	1.91e-04	162	31	3	afffecc6c504930554aafc12c5bffa53e3c5b016
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NFASC CACNA1H ARHGEF17	1.95e-04	163	31	3	8f24cef152f5965727bbeee116bd26c75cbba82a
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 COL12A1 RYR2	2.02e-04	165	31	3	6d315e0734079ad05336cc2c3f24d870c9105bc8
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 COL12A1 RYR2	2.02e-04	165	31	3	84f5597b1bb75f42de9a224196bb8ac198bbe3bf
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NFASC CACNA1H RYR2	2.02e-04	165	31	3	8a82e20c9b1156bb4bbc16f7785abb04458d671b
Drug	manidipine	PPIG CACNA1H FGG RYR2 RYR3	1.77e-07	95	31	5	CID000004008
Drug	Tropine [120-29-6]; Down 200; 28.4uM; PC3; HT_HG-U133A	TPR ATP7B ARHGEF17 RYR2 RECQL5 TJP3	2.46e-07	198	31	6	5790_DN
Drug	AC1L1D8L	PPIG RYR2 RYR3 PGR	2.56e-06	71	31	4	CID000002241
Drug	ethosuximide	PPIG CACNA1H RYR2 RYR3	3.03e-06	74	31	4	CID000003291
Drug	felodipine	PPIG CACNA1H RYR2 RYR3 PGR	3.09e-06	169	31	5	CID000003333
Drug	nisoldipine	PPIG CACNA1H RYR2 RYR3	3.74e-06	78	31	4	CID000004499
Drug	AC1L1HMM	ITGA6 PPIG CACNA1H HSF1 HNRNPUL2 POLD2 PGR	4.84e-06	516	31	7	CID000004196
Drug	2-hydroxycarbazole	RYR2 RYR3	5.38e-06	3	31	2	CID000093551
Drug	cis-diammineplatinum(II	RYR2 RYR3	5.38e-06	3	31	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR2 RYR3	5.38e-06	3	31	2	CID002750949
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR2 RYR3	5.38e-06	3	31	2	CID005748312
Drug	8N3-cADPR	RYR2 RYR3	5.38e-06	3	31	2	CID000127713
Drug	aminodantrolene	RYR2 RYR3	5.38e-06	3	31	2	CID009570289
Drug	Epitiostanol [2363-58-8]; Up 200; 13uM; MCF7; HT_HG-U133A	ITGA6 CACNA1H CELSR2 RECQL5 PGR	5.61e-06	191	31	5	7342_UP
Drug	NSC759576	PPIG CACNA1H HSF1 RYR2 RYR3	5.61e-06	191	31	5	CID000003075
Drug	Mifepristone	TJP2 ITGA6 COL12A1 HSF1 POLD2 RYR2 PGR	7.61e-06	553	31	7	ctd:D015735
Drug	fenvalerate	PPIG CACNA1H FGG ATP7B	8.56e-06	96	31	4	CID000003347
Drug	PCB74	RYR2 RYR3	1.07e-05	4	31	2	CID000036218
Drug	148504-47-6	RYR2 RYR3	1.07e-05	4	31	2	CID006444275
Drug	SC 38249	RYR2 RYR3	1.07e-05	4	31	2	CID000134834
Drug	AC1L1U7A	RYR2 RYR3	1.07e-05	4	31	2	CID000035682
Drug	M3/M4	PPIG RYR2 RYR3	1.10e-05	32	31	3	CID000486507
Drug	CNS 1145	CACNA1H RYR2 RYR3	1.21e-05	33	31	3	CID000190902
Drug	IHC-64	CACNA1H RYR2 RYR3	1.21e-05	33	31	3	CID000162753
Drug	loperamide	PPIG CACNA1H RYR2 RYR3	1.22e-05	105	31	4	CID000003954
Drug	AC1L1KF5	FGG RYR2 RYR3 PGR	1.63e-05	113	31	4	CID000005470
Drug	Rgd Peptide	CHL1 ITGA6 MFAP4 COL12A1 FGG	1.66e-05	239	31	5	CID000104802
Drug	lamotrigine	PPIG CACNA1H RYR2 RYR3	1.81e-05	116	31	4	CID000003878
Drug	pimozide	PPIG CACNA1H RYR2 RYR3	2.58e-05	127	31	4	CID000016362
Drug	MBED	RYR2 RYR3	2.68e-05	6	31	2	CID000129958
Drug	chloro-m-cresol	RYR2 RYR3	2.68e-05	6	31	2	CID000012008
Drug	AC1O528X	RYR2 RYR3	2.68e-05	6	31	2	CID006475857
Drug	NSC114784	RYR2 RYR3	2.68e-05	6	31	2	CID000419425
Drug	Azumoleno	RYR2 RYR3	3.75e-05	7	31	2	CID000056259
Drug	Br2BAPTA	RYR2 RYR3	3.75e-05	7	31	2	CID003081001
Drug	[[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate	RYR2 RYR3	3.75e-05	7	31	2	CID009547999
Drug	Trp-Trp	TPR RYR2 RYR3	4.04e-05	49	31	3	CID000088656
Drug	Cinildipine	CACNA1H RYR2 RYR3	6.03e-05	56	31	3	CID000002752
Drug	AC-474	PPIG FGG PGR	7.06e-05	59	31	3	CID000002999
Drug	nilvadipine	CACNA1H RYR2 RYR3	7.42e-05	60	31	3	CID000004494
Drug	IAA-94	CACNA1H RYR2 RYR3	7.80e-05	61	31	3	CID000003667
Drug	gabapentin	PPIG CACNA1H RYR2 RYR3	7.88e-05	169	31	4	CID000003446
Drug	PCB 95	RYR2 RYR3	8.02e-05	10	31	2	CID000038012
Drug	norketobemidone	PPIG ATP7B	8.02e-05	10	31	2	CID000161154
Drug	lercanidipine	CACNA1H RYR2 RYR3	8.59e-05	63	31	3	CID000065866
Drug	riluzole	NFASC CACNA1H RYR2 RYR3	8.82e-05	174	31	4	CID000005070
Drug	mibefradil	PPIG CACNA1H RYR3	9.00e-05	64	31	3	CID000060662
Drug	TMB-8	TJP2 CACNA1H RYR2 RYR3	9.22e-05	176	31	4	CID000005494
Drug	PCB 66	RYR2 RYR3	9.79e-05	11	31	2	CID000036185
Drug	R 478	RYR2 RYR3	9.79e-05	11	31	2	CID000084223
Drug	8-amino-cADPR	RYR2 RYR3	9.79e-05	11	31	2	CID003081323
Drug	gallopamil	CACNA1H RYR2 RYR3	1.03e-04	67	31	3	CID000001234
Drug	Monensin sodium salt [22373-78-0]; Up 200; 5.8uM; PC3; HT_HG-U133A	MIA2 ARHGEF17 RECQL5 TJP3	1.07e-04	183	31	4	3704_UP
Drug	AC1L2AC7	CACNA1H RYR2 RYR3	1.13e-04	69	31	3	CID000068733
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	ITGA6 TPR PPIG HNRNPUL2	1.17e-04	187	31	4	4302_DN
Drug	Ryanodine	RYR2 RYR3	1.17e-04	12	31	2	ctd:D012433
Drug	chloro-s-triazine	PPIG PGR	1.17e-04	12	31	2	CID005215566
Drug	ATP,Gamma S	CACNA1H POLD2 RECQL5 MOCOS	1.21e-04	189	31	4	CID000002028
Drug	dihydropyridine	PPIG CACNA1H RYR2 RYR3	1.32e-04	193	31	4	CID000104822
Drug	CAS 298-57-7	CACNA1H RYR2 RYR3	1.33e-04	73	31	3	CID000002761
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A	ITGA6 CACNA1H HNRNPUL2 RECQL5	1.34e-04	194	31	4	4736_DN
Drug	Medrysone [2668-66-8]; Down 200; 11.6uM; MCF7; HT_HG-U133A	TPR CACNA1H RYR2 PGR	1.34e-04	194	31	4	4727_DN
Drug	Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A	TPR HNRNPUL2 RECQL5 TJP3	1.34e-04	194	31	4	4320_DN
Drug	Demeclocycline hydrochloride [64-73-3]; Down 200; 8uM; MCF7; HT_HG-U133A	CACNA1H MIA2 ARHGEF17 PGR	1.34e-04	194	31	4	3604_DN
Drug	Leflunomide [75706-12-6]; Up 200; 14.8uM; PC3; HT_HG-U133A	TPR CELSR2 RECQL5 TJP3	1.37e-04	195	31	4	5884_UP
Drug	tetralol	PPIG CACNA1H	1.39e-04	13	31	2	CID000010747
Drug	(R) -Naproxen sodium salt [26159-34-2]; Up 200; 15.8uM; HL60; HT_HG-U133A	ATP7B CELSR2 HSF1 RECQL5	1.40e-04	196	31	4	2533_UP
Drug	Betonicine [515-25-3]; Down 200; 25.2uM; MCF7; HT_HG-U133A	CACNA1H ARHGEF17 RECQL5 PGR	1.42e-04	197	31	4	4767_DN
Drug	Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; HL60; HT_HG-U133A	MIA2 RYR2 RECQL5 TJP3	1.42e-04	197	31	4	2554_DN
Drug	Apramycin [37321-09-8]; Up 200; 7.4uM; MCF7; HT_HG-U133A	ITGA6 CACNA1H HNRNPUL2 RECQL5	1.42e-04	197	31	4	7334_UP
Drug	Quinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; PC3; HT_HG-U133A	TPR ARHGEF17 RECQL5 TJP3	1.45e-04	198	31	4	5793_DN
Drug	CP-645525-01 [287190-82-3]; Up 200; 10uM; MCF7; HT_HG-U133A	ITGA6 CACNA1H ARHGEF17 RECQL5	1.45e-04	198	31	4	7515_UP
Drug	estradiol, USP; Down 200; 0.1uM; PC3; HT_HG-U133A	TPR MIA2 HNRNPUL2 TJP3	1.45e-04	198	31	4	4432_DN
Drug	pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A	TPR CACNA1H RECQL5 PGR	1.45e-04	198	31	4	7083_UP
Drug	Mifepristone [84371-65-3]; Up 200; 9.4uM; PC3; HT_HG-U133A	HNRNPUL2 PARP8 RYR2 RYR3	1.45e-04	198	31	4	5827_UP
Drug	Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; PC3; HT_HG-U133A	NFASC MIA2 RYR2 TJP3	1.48e-04	199	31	4	5842_UP
Drug	Aspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A	TPR CACNA1H ARHGEF17 RYR2	1.48e-04	199	31	4	3265_UP
Drug	Meglumine [6284-40-8]; Up 200; 20.4uM; HL60; HT_HG-U133A	ITGA6 FGG RYR2 RECQL5	1.51e-04	200	31	4	3068_UP
Drug	Thiamine hydrochloride [67-03-8]; Up 200; 11.8uM; MCF7; HT_HG-U133A	CACNA1H RYR2 PGR TJP3	1.51e-04	200	31	4	2894_UP
Drug	valproate	PPIG CACNA1H FGG RYR2 RYR3	1.52e-04	381	31	5	CID000003121
Drug	bimoclomol	HSF1 RYR3	1.62e-04	14	31	2	CID009576891
Drug	AC1O5K1I	PPIG PGR	1.62e-04	14	31	2	CID006435567
Drug	N-cyclopentyl-N-cyclobutylformamide	CACNA1H RYR2 RYR3	1.68e-04	79	31	3	CID005287890
Drug	cobalt-60	CACNA1H ATP7B HSF1 RYR2 RYR3	1.69e-04	390	31	5	CID000061492
Drug	FPL 64176	RYR2 RYR3	1.86e-04	15	31	2	CID000003423
Drug	Gvapspat amide	RYR2 RYR3	1.86e-04	15	31	2	CID000125015
Drug	Grgds	ITGA6 FGG MOCOS	1.95e-04	83	31	3	CID000123811
Drug	phenytoin	PPIG CACNA1H RYR2 RYR3	2.14e-04	219	31	4	CID000001775
Drug	nifedipine	PPIG CACNA1H ATP7B RYR2 RYR3	2.26e-04	415	31	5	CID000004485
Drug	kazinol B	RYR2 RYR3	2.41e-04	17	31	2	CID000480869
Drug	cyclophorine	PPIG CACNA1H RYR2 RYR3 PGR	2.55e-04	426	31	5	CID000002909
Drug	methylcoumarin	RYR2 RYR3	2.71e-04	18	31	2	CID000007092
Drug	AC1L1GHE	TAF1L POLD2 PGR	3.00e-04	96	31	3	CID000003684
Drug	FR h	ATP7B HSF1	3.02e-04	19	31	2	CID005288251
Drug	AC1L380G	RYR2 RYR3	3.02e-04	19	31	2	CID000084698
Drug	norgestimate	FGG PGR	3.02e-04	19	31	2	ctd:C017576
Drug	AC1MW7VF	RYR2 RYR3	3.02e-04	19	31	2	CID000414699
Drug	cadmium	CACNA1H ATP7B HSF1 RYR3 PGR	3.05e-04	443	31	5	CID000002514
Drug	isotetrandrine	CACNA1H RYR2 RYR3	3.09e-04	97	31	3	CID000005422
Drug	nitrendipine	CACNA1H RYR2 RYR3	3.18e-04	98	31	3	CID000004507
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR2 RYR3	3.00e-06	3	30	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR2 RYR3	3.00e-06	3	30	2	DOID:8545 (implicated_via_orthology)
Disease	MASA syndrome (implicated_via_orthology)	CHL1 NFASC	2.09e-05	7	30	2	DOID:0060246 (implicated_via_orthology)
Disease	serum alanine aminotransferase measurement	CHL1 TJP2 COL12A1 CELSR2 ZC3H4 TJP3	2.08e-04	869	30	6	EFO_0004735
Disease	glutamate measurement	TAF1L PARP8	3.99e-04	29	30	2	EFO_0010487
Disease	complement factor H-related protein 2 measurement	CHL1 COL12A1	3.99e-04	29	30	2	EFO_0600055
Disease	diabetic nephropathy	ITGA6 RYR3 PGR	4.73e-04	150	30	3	EFO_0000401
Disease	epilepsy (implicated_via_orthology)	CHL1 ITGA6 NFASC	6.02e-04	163	30	3	DOID:1826 (implicated_via_orthology)
Disease	pulmonary hypertension (biomarker_via_orthology)	RYR2 RYR3	3.01e-03	80	30	2	DOID:6432 (biomarker_via_orthology)
Disease	hormone measurement	ZC3H4 RYR2	3.31e-03	84	30	2	EFO_0004730
Disease	Drug toxicity	CACNA1H MOCOS	3.31e-03	84	30	2	C0013221
Disease	Adverse reaction to drug	CACNA1H MOCOS	3.31e-03	84	30	2	C0041755

Protein segments in the cluster

Peptide	Gene	Start	Entry
DFGDFGDFGSASGST	AFTPH	431	Q6ULP2
SFAFDNVGYEGGLDG	ATP7B	36	P35670
FYTFQGGDDGDGDFI	CELSR2	851	Q9HCU4
SLFYDSGDGFGDEGA	RAD21L1	196	Q9H4I0
DGYEDFRLSSGGGSS	ARHGEF17	2031	Q96PE2
DSEGDNDSEEFYYGG	PARP8	126	Q8N3A8
EYGEGDHGLFSEDGS	CHL1	1166	O00533
SFSGFGAEDDDLGGL	POLD2	451	P49005
LFELGEGSYFSEGDG	HSF1	491	Q00613
EGSYFSEGDGFAEDP	HSF1	496	Q00613
QLGEDEFSYGFDGRG	HNRNPUL2	326	Q1KMD3
GGGTASAYLAGEDFY	MOCOS	291	Q96EN8
FDGEGLASSFGYDVA	ITGA6	346	P23229
GGESIYGGFFEDESF	PPIG	86	Q13427
DESYDGGAGAASAFA	PGR	326	P06401
YGEGGEGQFNEDGSF	NFASC	1301	O94856
YFAGGDAGDAFDGFD	FGG	306	P02679
LYASGAGDALFGEGT	COL12A1	886	Q99715
GDESFLGTYLTGGEG	DNAAF9	531	Q5TEA3
GSESGDSDGRGVYEF	CACNA1H	716	O95180
SGDGSVFKSEGAYFG	C5orf34	356	Q96MH7
NGVGDDLFSYGFDGL	RYR2	716	Q92736
GGGFTSYLGFGDEDT	MIA2	311	Q96PC5
MSYFDNGEDFGGDSD	POLR3GL	196	Q9BT43
MLGVSEDGSGFDYGF	TAF1L	371	Q8IZX4
YTLFVAGFEDGGAGD	MFAP4	161	P55083
FSRYDEGSGGSGDEG	RECQL5	481	O94762
DFEDTDGEGGAYTDN	TJP2	921	Q9UDY2
GTGSADGNDGYEADD	TPR	1991	P12270
GGNGVGDDLYSYGFD	RYR3	701	Q15413
EDFYDEDMGDGGGGS	ZC3H4	361	Q9UPT8
DYETDGEGGAYTDGE	TJP3	806	O95049